3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Hematologic Neoplasms
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Interventions
Rituximab
45
Cyclophosphamide
32
Lenalidomide
24
fludarabine
20
zanubrutinib
14
venetoclax
12
obinutuzumab
12
orelabrutinib
11
fludarabine phosphate
10
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
10
Whole-Body Irradiation
8
Specimen Handling
8
Prednisone
8
pirtobrutinib
7
ibrutinib
7
Vincristine
7
CT-P10
7
Biopsy
7
Mycophenolic Acid
6
Doxorubicin
5
tafasitamab
4
polatuzumab vedotin
3
pembrolizumab
3
acalabrutinib
3
Tacrolimus
3
Sirolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
capivasertib
×
1 year
×
Clear all
No trials found.